Literature DB >> 22050449

Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial.

N Manabe1, K Haruma, M Ito, N Takahashi, H Takasugi, Y Wada, H Nakata, T Katoh, M Miyamoto, S Tanaka.   

Abstract

Nonerosive reflux disease (NERD) is the most common form of gastroesophageal reflux disease. Patients with NERD have a lower response rate to proton pump inhibitors (PPIs) than patients with erosive esophagitis when gauged from relief of heartburn. Sodium alginate decreases the acidity of refluxate and protects the esophageal mucosa. However, whether the addition of sodium alginate to PPI therapy can improve NERD symptoms remains unknown. Accordingly, the aim of this study was to evaluate the efficacy of adding sodium alginate to basal PPI therapy for NERD. Patients who had experienced heartburn on at least 2 days per week during the 1-month period before entering the study and had no endoscopic mucosal breaks (grade M or N according to Hoshihara's modification of the Los Angeles classification) were randomized to one of two treatments for 4 weeks: omeprazole (20 mg once daily) plus sodium alginate (30 mL four times a day) (group A) or omeprazole (20 mg once daily) alone (group B). Eighty-seven patients were enrolled, and 76 patients were randomly assigned to group A (n = 36) or group B (n = 40). Complete resolution of heartburn for at least 7 consecutive days by the end of treatment was significantly more common in group A (56.7%) than in group B (25.7%). One patient from group A had mild drug-related diarrhea that was not clinically serious. In conclusion, omeprazole combined with sodium alginate was better than omeprazole alone in Japanese patients with NERD.
© 2011 Copyright the Authors. Journal compilation © 2011, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22050449     DOI: 10.1111/j.1442-2050.2011.01276.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  22 in total

Review 1.  Management of the patient with incomplete response to PPI therapy.

Authors:  Peter J Kahrilas; Guy Boeckxstaens; Andre J P M Smout
Journal:  Best Pract Res Clin Gastroenterol       Date:  2013-06       Impact factor: 3.043

Review 2.  Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.

Authors:  Yu-Min Kung; Wen-Hung Hsu; Meng-Chieh Wu; Jiunn-Wei Wang; Chung-Jung Liu; Yu-Chung Su; Chao-Hung Kuo; Fu-Chen Kuo; Deng-Chyang Wu; Yao-Kuang Wang
Journal:  Dig Dis Sci       Date:  2017-11-06       Impact factor: 3.199

3.  Alginates: From the ocean to gastroesophageal reflux disease treatment.

Authors:  Serhat Bor; İsmail Hakkı Kalkan; Altay Çelebi; Dinç Dinçer; Filiz Akyüz; Peter Dettmar; Hasan Özen
Journal:  Turk J Gastroenterol       Date:  2019-09       Impact factor: 1.852

4.  Symptomatic response to GERDOFF® in patients with gastro-esophageal reflux disease and poor response to alginates: an exploratory, post-market, open-label study.

Authors:  Valentina Boarino; Ivana Raguzzi; Margherita Marocchi; Alberto Merighi
Journal:  Turk J Gastroenterol       Date:  2020-06       Impact factor: 1.852

Review 5.  Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis.

Authors:  D A Leiman; B P Riff; S Morgan; D C Metz; G W Falk; B French; C A Umscheid; J D Lewis
Journal:  Dis Esophagus       Date:  2017-05-01       Impact factor: 3.429

6.  Alginate controls heartburn in patients with erosive and nonerosive reflux disease.

Authors:  Edoardo Savarino; Nicola de Bortoli; Patrizia Zentilin; Irene Martinucci; Luca Bruzzone; Manuele Furnari; Santino Marchi; Vincenzo Savarino
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

7.  Sodium alginate ameliorates indomethacin-induced gastrointestinal mucosal injury via inhibiting translocation in rats.

Authors:  Atsuki Yamamoto; Tomokazu Itoh; Reishi Nasu; Ryuichi Nishida
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

8.  OM2, a Novel Oligomannuronate-Chromium(III) Complex, Promotes Mitochondrial Biogenesis and Lipid Metabolism in 3T3-L1 Adipocytes via the AMPK-PGC1α Pathway.

Authors:  Jiejie Hao; Cui Hao; Lijuan Zhang; Xin Liu; Xiaolin Zhou; Yunlou Dun; Haihua Li; Guangsheng Li; Xiaoliang Zhao; Yuanyuan An; Jiankang Liu; Guangli Yu
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

9.  Non-acid reflux and sleep apnea: the importance of drug induced sleep endoscopy.

Authors:  Carlos O'Connor-Reina; Jose Maria Ignacio Garcia; Peter Baptista; Maria Teresa Garcia-Iriarte; Carlos Casado Alba; Monica Perona; Paz Francisca Borrmann; Laura Rodriguez Alcala; Guillermo Plaza
Journal:  J Otolaryngol Head Neck Surg       Date:  2021-06-30

10.  Current pharmacological management of gastroesophageal reflux disease.

Authors:  Yao-Kuang Wang; Wen-Hung Hsu; Sophie S W Wang; Chien-Yu Lu; Fu-Chen Kuo; Yu-Chung Su; Sheau-Fang Yang; Chiao-Yun Chen; Deng-Chyang Wu; Chao-Hung Kuo
Journal:  Gastroenterol Res Pract       Date:  2013-06-26       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.